Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Study of patient-reported outcomes and survival and adverse events in daratumumab-treated myeloma finds (surprisingly!) low physical function patients experienced greater OS and PFS benefit.”

“Predictive and Prognostic Significance of Patient-Reported Outcomes for Survival and Adverse Events in Daratumumab-Treated Multiple Myeloma”

Authors: Ahmad Abuhelwa, Sara Almansour, Ethan Basch, Humaid Al-Shamsi, Ziad Abuhelwa, Yasser Bustanji, Mohammad Semreen, Zelal Kharaba, Salma Ali, Rawan Mohamed, Ganessan Kichenadasse, Ross McKinnon, Michael Sorich, Karem Alzoubi, Ashley Hopkins.

Myeloma Paper of the Day, March 15th, suggested by Robert Orlowski

More posts featuring Robert Orlowski.